TVTX Travere Therapeutics, Inc.
$50.88▲ +1.82%
Healthcare
Other
Volume 3.31M
Avg Volume (10D) 2.05M
Key Metrics & Fundamentals
Market Cap
$4.80B
P/E Ratio
–
Div Yield
0.00%
52W Range
22.59 - 68.73
% vs 50 MA
-15.07%
% vs 200 MA
9.85%
RSI-14
36.8
MACD Histogram
+0.1000
Beta (1Y vs SPY)
1.37
Free Cash Flow
$37.00M
Gross Rev
$169.58M
Gross Profit
$160.35M
EBITDA
-$28.63M
COGS
$9.24M
Operating Exp
$156.40M
Operating Income
$3.95M
EBIT
$3.95M
Pretax Income
-$35.00M
Net Income
-$34.80M
EPS (Diluted)
-0.37
Price & Volume History
Loading chart…
Recent News
Travere Therapeutics to Report Third Quarter 2026 Financial Results
Business Wire · Oct 26, 2026 4:30 PM ET
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
Business Wire · Oct 23, 2026 7:20 PM ET
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy
Zacks · Oct 22, 2026 10:27 AM ET
Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to Decline
Zacks · Oct 22, 2026 9:00 AM ET
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · Oct 12, 2026 5:00 PM ET
Travere Therapeutics (TVTX) Is Down 6.7% After New FILSPARI Data And Patent Extension - What's Changed
Simply Wall St. · Oct 7, 2026 2:10 AM ET
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
Business Wire · Oct 2, 2026 10:00 AM ET
Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI
MT Newswires · Sep 23, 2026 7:49 AM ET
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
Business Wire · Sep 23, 2026 7:00 AM ET
Travere Therapeutics (TVTX) Sets CEO Handover For December 2026
Simply Wall St. · Sep 22, 2026 9:13 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See TVTX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.